[{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Marizomib","moa":"20S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Secura Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Marizomib","moa":"20S proteasome","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Secura Bio","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Secura Bio"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Takeda Pharmaceutical | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical | Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ixazomib Citrate","moa":"26S proteasome","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Boston Children's Hospital | Washington University School of Medicine | Medical College of Wisconsin | Johns Hopkins University | La Jolla Institute for Allergy & Immunology | National Heart, Lung, and Blood Institute | Aste","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Regadenoson Monohydrate","moa":"Adenosine A2a receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Boston Children's Hospital | Washington University School of Medicine | Medical College of Wisconsin | Johns Hopkins University | La Jolla Institute for Allergy & Immunology | National Heart, Lung, and Blood Institute | Aste","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Boston Children's Hospital | Washington University School of Medicine | Medical College of Wisconsin | Johns Hopkins University | La Jolla Institute for Allergy & Immunology | National Heart, Lung, and Blood Institute | Aste"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"HPAPI","year":"2016","type":"Inapplicable","leadProduct":"Apalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG | Decipher Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bicalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG | Decipher Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG | Decipher Biosciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Medivation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Medivation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Medivation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Medivation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Medivation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Medivation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Medivation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Medivation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Medivation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"AMG386","moa":"Angiopoietin-1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Amgen Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Amgen Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Agreement","leadProduct":"Salinomycin","moa":"antibiotics (Streptomyces strains); anti-inflammatory agents (salicylic acid derivatives)","graph1":"Oncology","graph2":"IND Enabling","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"5","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca | Genentech | National Institutes of Health | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca | Genentech | National Institutes of Health | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca | Genentech | National Institutes of Health | National Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ BeOne Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ BeOne Medicines"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc | Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase III","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Servier","highestDevelopmentStatusID":"10","companyTruncated":"Dana-Farber Cancer Institute \/ Servier"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Leadiant Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Peg L asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Leadiant Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Leadiant Biosciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Axicabtagene Ciloleucel","moa":"||B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Brexucabtagene Autoleucel","moa":"||B-lymphocyte antigen CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dana-Farber Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Immunology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Obinutuzumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Comprehensive Cancer Network | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Ofatumumab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ National Comprehensive Cancer Network | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ National Comprehensive Cancer Network | GSK"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Rituximab","moa":"B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Institutes of Health | Candel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"rQNestin34.5v.2","moa":"Cancer cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ National Institutes of Health | Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ National Institutes of Health | Candel Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"TG Therapeutics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Umbralisib Tosylate","moa":"Casein kinase I epsilon | PI3-kinase p110-delta subunit | Tyrosine-protein kinase ABL","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ TG Therapeutics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ TG Therapeutics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"BHV-1100","moa":"CD-38","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Palbociclib","moa":"CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lenalidomide","moa":"CRL4(CRBN) E3 ubiquitin ligase","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MCS110","moa":"CSF1R","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ulocuplumab","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ulocuplumab","moa":"C-X-C chemokine receptor type 4","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Autologous Cytokine Induced Memory-Like NK Cell","moa":"||Cyclic ADP-ribose hydrolase 1 (CD38)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BAY1000394","moa":"Cyclin-dependent kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ribociclib","moa":"Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly | Effector Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly | Effector Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly | Effector Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Tremelimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"HiberCell","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Odetiglucan","moa":"Dectin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ HiberCell","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ HiberCell"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Myriad genetics | Translational Breast Cancer Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Myriad genetics | Translational Breast Cancer Research Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Myriad genetics | Translational Breast Cancer Research Consortium"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cisplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Carboplatin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Sanofi"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca | Cyclacel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sapacitabine","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca | Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca | Cyclacel Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Stemline Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Stemline Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Stemline Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"DNA | Glutamate carboxypeptidase II","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kite Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Kite Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Kite Pharma"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Binimetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 1 | Dual specificity mitogen-activated protein kinase kinase 2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation | National Comprehensive Cancer Network","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Trametinib","moa":"Dual specificity mitogen-activated protein kinase kinase; MEK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | National Comprehensive Cancer Network","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | National Comprehensive Cancer Network"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Effector Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Astellas Pharma | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Crizotinib","moa":"EML4-ALK | Hepatocyte growth factor receptor | ALK tyrosine kinase receptor | NPM\/ALK (Nucleophosmin\/ALK tyrosine kinase receptor)","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Astellas Pharma | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Astellas Pharma | Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Belzutifan","moa":"Endothelial PAS domain-containing protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Erlotinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Astellas Pharma"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Gefitinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Osimertinib Mesylate","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Translational Breast Cancer Research Consortium | Puma Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"CAS 698387-09-6","moa":"Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2 | Receptor protein-tyrosine kinase erbB-4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Translational Breast Cancer Research Consortium | Puma Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Translational Breast Cancer Research Consortium | Puma Biotechnology"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tamoxifen Citrate","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"William Lawrence and Blanche Hughes Foundation | Karyopharm Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2014","type":"Inapplicable","leadProduct":"Selinexor","moa":"Exportin-1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ William Lawrence and Blanche Hughes Foundation | Karyopharm Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ William Lawrence and Blanche Hughes Foundation | Karyopharm Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Allergan"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Rogaratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Novartis Pharmaceuticals Corporation | AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Novartis Pharmaceuticals Corporation | AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Novartis Pharmaceuticals Corporation | AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"EpicentRx","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RRx-001","moa":"||Free radical (FRD)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"SpringWorks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Nirogacestat Hydrobromide","moa":"||Gamma-secretase","graph1":"Oncology","graph2":"Preclinical","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Dana-Farber Cancer Institute \/ SpringWorks Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2011","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Amgen Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Cancer Institute | Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ National Cancer Institute | Eisai Inc","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ National Cancer Institute | Eisai Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Prostate Cancer Foundation | Pfizer Inc | Myovant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Relugolix","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Prostate Cancer Foundation | Pfizer Inc | Myovant Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Prostate Cancer Foundation | Pfizer Inc | Myovant Sciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Gonadorelin","moa":"Gonadotropin-releasing hormone receptor; Putative gonadotropin-releasing hormone II receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Partner Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Partner Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Partner Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Brigham and Women's Hospital | Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Brigham and Women's Hospital | Madrigal Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Brigham and Women's Hospital | Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Madrigal Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ADX-1612","moa":"Heat shock protein HSP90","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Madrigal Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Madrigal Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Merestinib","moa":"Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Panobinostat lactate","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Curis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fimepinostat","moa":"Histone deacetylase | PI3-kinase p110-beta subunit | PI3-kinase p110-alpha subunit | PI3-kinase p110-delta subunit||PI3-kinase p110-beta subunit | PI3-kinase p110-alpha subunit | Histone deacetylase | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Curis","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Curis"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Acetylon Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ricolinostat","moa":"Histone deacetylase 6","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Acetylon Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Acetylon Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Immunology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1 | Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Biogen","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Biogen"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Miltenyi Biomedicine | Iovance Biotherapeutics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Miltenyi Biomedicine | Iovance Biotherapeutics | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Miltenyi Biomedicine | Iovance Biotherapeutics | National Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"PROMETHEUS LABS","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Immunology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ PROMETHEUS LABS","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ PROMETHEUS LABS"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Cancer Institute | PROMETHEUS LABS","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Interleukin-2","moa":"Interleukin-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ National Cancer Institute | PROMETHEUS LABS","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ National Cancer Institute | PROMETHEUS LABS"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership | Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Hematology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership | Leukemia and Lymphoma Society","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership | Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Incyte Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Massachusetts General Hospital | Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Massachusetts General Hospital | Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Massachusetts General Hospital | Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | GSK"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Beth Israel Deaconess Medical Center | Brigham and Women's Hospital | GSK | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Brigham and Women's Hospital | GSK | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Brigham and Women's Hospital | GSK | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pazopanib Hydrochloride","moa":"Macrophage colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"BioMed Valley Discoveries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ulixertinib","moa":"MAP kinase ERK2 | MAP kinase ERK1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ BioMed Valley Discoveries","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ BioMed Valley Discoveries"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"LY3214996","moa":"Mitogen-activated protein kinase; ERK1\/ERK2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"LY3300054","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"NH TherAguix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Gadolinium-Based Nanoparticle","moa":"MRI contrast","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ NH TherAguix","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ NH TherAguix"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genus Oncology, LLC | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"GO-203-2c","moa":"Mucin-1 (MUC1)","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genus Oncology, LLC | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Genus Oncology, LLC | National Institutes of Health"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"The Ben & Catherine Ivy Foundation | Accelerate Brain Cancer Cure | Merck & Co | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Personalized Neoantigen Peptides","moa":"Neoantigen-targeting T-cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ The Ben & Catherine Ivy Foundation | Accelerate Brain Cancer Cure | Merck & Co | National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ The Ben & Catherine Ivy Foundation | Accelerate Brain Cancer Cure | Merck & Co | National Institutes of Health"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"BrainStorm Cell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CIML NK Cell","moa":"NK cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ ImmunityBio","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ ImmunityBio"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kidney Cancer Association","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"CIML NK Cell","moa":"NK cell","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Kidney Cancer Association","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Kidney Cancer Association"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Beth Israel Deaconess Medical Center | Akorn Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Indocyanine Green","moa":"None","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Akorn Inc","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Beth Israel Deaconess Medical Center | Akorn Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"TeamConnor Childhood Cancer Foundation | Cookies for Kids' Cancer | Aileron Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"ALRN-6924","moa":"p53-binding protein Mdm4 (MDM4)","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ TeamConnor Childhood Cancer Foundation | Cookies for Kids' Cancer | Aileron Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ TeamConnor Childhood Cancer Foundation | Cookies for Kids' Cancer | Aileron Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Osteosarcoma Institute | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Osteosarcoma Institute | AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Osteosarcoma Institute | AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Cemiplimab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Immunogen | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Immunogen | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Immunogen | Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co | Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co | Amgen Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech | Stand Up To Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech | Stand Up To Cancer","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech | Stand Up To Cancer"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ EMD Serono","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ EMD Serono"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"LY3022855","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Buparlisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation | AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Buparlisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Paxalisib","moa":"PI3-kinase class I","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Gilead Sciences | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Idelalisib","moa":"PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Gilead Sciences | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Gilead Sciences | GSK"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Idelalisib","moa":"PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Gilead Sciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Copanlisib","moa":"PI3-kinase p110-delta subunit | PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc | Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc | Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Secura Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Secura Bio","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Secura Bio"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Secura Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Duvelisib","moa":"PI3-kinase p110-gamma subunit | PI3-kinase p110-delta subunit","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Secura Bio","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Secura Bio"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sunitinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor | Vascular endothelial growth factor receptor 1 | Vascular endothelial growth factor receptor 3 | Tyrosine-protein kinase receptor RET | Macrophage colony stimulating factor receptor | Vascular endothelial growth factor receptor 2 | Tyrosine-protein kinase receptor FLT3 | Platelet-derived growth factor receptor beta","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG | Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG | Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Tesaro","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Tesaro","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Tesaro"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Translational Breast Cancer Research Consortium | Johns Hopkins University | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niraparib Tosylate","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Translational Breast Cancer Research Consortium | Johns Hopkins University | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Translational Breast Cancer Research Consortium | Johns Hopkins University | GSK"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Epizyme | Pfizer Inc | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Talazoparib","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Epizyme | Pfizer Inc | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Epizyme | Pfizer Inc | National Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Talazoparib","moa":"Poly [ADP-ribose] polymerase-1 | Poly [ADP-ribose] polymerase 2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Potassium\/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Amgen Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Durvalumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Dental and Oral Health","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Multiple Myeloma Research Consortium | Blood Cancer Research Partnership"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Exelixis"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Exelixis"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"ImmunityBio | Bristol Myers Squibb | Miltenyi Biomedicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"N-803","moa":"receptor molecules","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ ImmunityBio | Bristol Myers Squibb | Miltenyi Biomedicine","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ ImmunityBio | Bristol Myers Squibb | Miltenyi Biomedicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pfizer Inc | Breast Cancer Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ARRY-380","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pfizer Inc | Breast Cancer Research Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Pfizer Inc | Breast Cancer Research Foundation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eisai Inc | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eisai Inc | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eisai Inc | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pertuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Beth Israel Deaconess Medical Center | Massachusetts General Hospital | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Trastuzumab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Kazia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tucatinib","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Kadcyla","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2014","type":"Inapplicable","leadProduct":"Kadcyla","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2017","type":"Inapplicable","leadProduct":"Kadcyla","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Trastuzumab Emtansine","moa":"Receptor protein-tyrosine kinase erbB-2 | Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Puma Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Neratinib","moa":"Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Puma Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Puma Biotechnology"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tazarotene","moa":"Retinoic acid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Sanofi | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Sanofi | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Sanofi | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2017","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Sanofi | St. Baldrick's Foundation | Cookies for Kids' Cancer | North American Consortium for Histiocytosis","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Clofarabine","moa":"Ribonucleoside-diphosphate reductase RR1 | DNA polymerase (alpha\/delta\/epsilon) | DNA","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Sanofi | St. Baldrick's Foundation | Cookies for Kids' Cancer | North American Consortium for Histiocytosis","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Sanofi | St. Baldrick's Foundation | Cookies for Kids' Cancer | North American Consortium for Histiocytosis"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Memorial Sloan Kettering Cancer Center | University of California, Los Angeles | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"MK2206","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Memorial Sloan Kettering Cancer Center | University of California, Los Angeles | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Beth Israel Deaconess Medical Center | Memorial Sloan Kettering Cancer Center | University of California, Los Angeles | Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Regorafenib","moa":"Serine\/threonine-protein kinase B-raf | Nerve growth factor receptor Trk-A | Tyrosine-protein kinase FRK | Fibroblast growth factor receptor 2 | MAP kinase p38 beta | Tyrosine-protein kinase ABL | Stem cell growth factor receptor | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Serine\/threonine-protein kinase RAF | Platelet-derived growth factor receptor | Tyrosine-protein kinase receptor RET | Discoidin domain-containing receptor 2 | Ephrin type-A receptor 2 | Tyrosine-protein kinase TIE-2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bayer AG"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Prexasertib","moa":"Serine\/threonine-protein kinase Chk2 | Serine\/threonine-protein kinase Chk1","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sapanisertib","moa":"Serine\/threonine-protein kinase mTOR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Adavosertib","moa":"Serine\/threonine-protein kinase WEE1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AstraZeneca"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Bristol Myers Squibb | Blood Cancer Research Partnership | Multiple Myeloma Research Consortium | Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Bristol Myers Squibb | Blood Cancer Research Partnership | Multiple Myeloma Research Consortium | Leukemia and Lymphoma Society","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Bristol Myers Squibb | Blood Cancer Research Partnership | Multiple Myeloma Research Consortium | Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Elotuzumab","moa":"SLAM family member 7","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Regeneron Pharmaceuticals | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PTZ-201","moa":"T-cell immunoreceptor with Ig and ITIM domains","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Regeneron Pharmaceuticals | Astellas Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Regeneron Pharmaceuticals | Astellas Pharma"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Alefacept","moa":"T-cell surface antigen CD2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Astellas Pharma"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Paxman Coolers | AstraZeneca | Eisai Inc | Daiichi Sankyo | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Paxman Coolers | AstraZeneca | Eisai Inc | Daiichi Sankyo | Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Paxman Coolers | AstraZeneca | Eisai Inc | Daiichi Sankyo | Gilead Sciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eisai Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eisai Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Eribulin","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"MacroGenics | Translational Breast Cancer Research Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ MacroGenics | Translational Breast Cancer Research Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ MacroGenics | Translational Breast Cancer Research Consortium"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Celgene Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Celgene Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Celgene Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Invios","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Ciltacabtagene Autoleucel","moa":"Tumor necrosis factor receptor superfamily member 17","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Gilead Sciences | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Gilead Sciences | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Gilead Sciences | Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Sacituzumab Govitecan","moa":"Tumor-associated calcium signal transducer 2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Gilead Sciences"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pharmacyclics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pharmacyclics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pharmacyclics | Leukemia and Lymphoma Society | Blood Cancer Research Partnership"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Pharmacyclics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AbbVie Inc | Pharmacyclics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AbbVie Inc | Pharmacyclics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ AbbVie Inc | Pharmacyclics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ibrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pirtobrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Incyte Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Incyte Corporation"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Celldex Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CDX-301","moa":"Tyrosine-protein kinase receptor FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Celldex Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Celldex Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Alectinib Hydrochloride","moa":"Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"223-Ra","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"NH TherAguix","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Aguix","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ NH TherAguix","highestDevelopmentStatusID":"7","companyTruncated":"Dana-Farber Cancer Institute \/ NH TherAguix"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"ImmunityBio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Cytokine Induced Memory-Like Natural Killer Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Ensure","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Abbott Laboratories"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Entrinsic Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Enterade","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Entrinsic Health","highestDevelopmentStatusID":"1","companyTruncated":"Dana-Farber Cancer Institute \/ Entrinsic Health"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Ferumoxytol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Undisclosed"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Oncovir | BioNTech | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Neoantigen-Based Personalized Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Oncovir | BioNTech | Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Oncovir | BioNTech | Merck & Co"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Red Queen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Licensing Agreement","leadProduct":"RQ-01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Red Queen Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ Red Queen Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"SHIRE PLC | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"SC-PEG","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ SHIRE PLC | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ SHIRE PLC | National Cancer Institute"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"VBL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VB11","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ VBL Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ VBL Therapeutics"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Brigham and Women's Hospital | Massachusetts General Hospital | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Brigham and Women's Hospital | Massachusetts General Hospital | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Bristol Myers Squibb | Clovis Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Clovis Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Bristol Myers Squibb | Clovis Oncology"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Comprehensive Cancer Network | AVEO Pharmaceuticals, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tivozanib","moa":"Vascular endothelial growth factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ National Comprehensive Cancer Network | AVEO Pharmaceuticals, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ National Comprehensive Cancer Network | AVEO Pharmaceuticals, Inc"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Exelixis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Exelixis","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Exelixis"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Exelixis | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Exelixis | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Exelixis | Genentech"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Ramucirumab","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dana-Farber Cancer Institute \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Eli Lilly"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"National Cancer Institute | Pharmavite","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dana-Farber Cancer Institute \/ National Cancer Institute | Pharmavite","highestDevelopmentStatusID":"6","companyTruncated":"Dana-Farber Cancer Institute \/ National Cancer Institute | Pharmavite"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Hale Family Center for Pancreatic Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Dana-Farber Cancer Institute","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"Dana-Farber Cancer Institute \/ Hale Family Center for Pancreatic Cancer Research"}]

Find Clinical Drug Pipeline Developments & Deals by Dana-Farber Cancer Institute

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : 177Lu-PSMA-617 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Renal Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 11, 2025

                          Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : NeoVax is a combination of neoantigen peptides and poly-ICLC which is being evaluated in combination with ipilimumab for the treatment of renal cell carcinoma.

                          Product Name : NeoVax

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 06, 2025

                          Lead Product(s) : Neoantigen-Based Personalized Vaccine,NEO-PV-01,Ipilimumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Dana-Farber grants Red Queen exclusive license to stapled lipopeptide COVID-19 therapeutics, incorporates additional exclusive patent rights covering RSV therapeutics.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Undisclosed

                          December 03, 2024

                          Lead Product(s) : RQ-01

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Red Queen Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Belzutifan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 06, 2024

                          Lead Product(s) : Belzutifan

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : The collaboration aims to conduct an investigator-sponsored trial evaluating zotatifin in patients with estrogen receptor-positive endometrial cancer and low-grade serous ovarian cancer.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          May 20, 2024

                          Lead Product(s) : Zotatifin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Effector Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Abemaciclib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Endometrial Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 15, 2024

                          Lead Product(s) : Abemaciclib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Eli Lilly

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : CIML NK Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          March 20, 2024

                          Lead Product(s) : CIML NK Cell

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : ImmunityBio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : CIML NK Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Renal Cell.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          March 19, 2024

                          Lead Product(s) : CIML NK Cell

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Kidney Cancer Association

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : Carboplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 12, 2024

                          Lead Product(s) : Carboplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Novartis Pharmaceuticals Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ISPE Annual Meeting
                          Not Confirmed
                          ISPE Annual Meeting
                          Not Confirmed

                          Details : The collaboration aims to evaluate invIOs’ small molecule INV501 that can selectively enhance anti-tumor immune responses, as a potential treatment for glioblastoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          November 09, 2023

                          Lead Product(s) : INV501

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Invios

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank